Date: 2018-09-03
Type of
information: Publication of results in a medical journal
phase:
Announcement: publication of results in Precision Oncology
Company: BioInvent (Sweden)
Product:
Action
mechanism:
Disease:
Therapeutic
area: Cancer - Oncology - Technology - Services
Country:
Trial
details:
Latest
news:
- • On September 3, 2018, BioInvent announced the publication of data confirming the power of its integrated technology platform for discovery of clinically relevant oncology targets and therapeutic antibodies. The article is published by BioInvent researchers in collaboration with Professor Mats Ohlin’s team at Lund University, and clinical researchers at the Hematology and Oncology Departments at Skåne University Hospital. It describes how the application of phenotypic F.I.R.S.T.™ discovery enables efficient identification of therapeutic antibody-target combinations. It thereby confirms the relevance of the company’s integrated technology platform, which comprises the n-CoDeR® antibody library and the unique F.I.R.S.T.™ development tool, for discovery of clinically relevant oncology targets and therapeutic antibodies.
- The research demonstrated that when F.I.R.S.T.™ was applied to cancer cells from patients with chronic lymphocytic leukemia (CLL), it resulted in discovery of antibodies and associated targets with improved cytotoxicity compared to the standard of care CD20-specific antibody rituximab. Enhanced antibody efficacy was confirmed in vivo using patient-derived xenograft models that retain the tumor’s sensitivity or resistance to rituximab. The data identified Fc?RIIB as a promising target for antibody based direct-targeting of CLL cells, contributing to the rationale for BioInvent’s ongoing clinical development of the Fc?RIIB-specific antibody BI-1206 in Fc?RIIB-positive B cell malignancy.
- The paper is titled “A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia”, (npj Precision Oncology)
Is
general: Yes
